Global Microbiome Therapeutics Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MARKET OVERVIEW<br />
The Human <strong>Microbiome</strong> Project, which was conducted in 2012, reported that more than<br />
10,000 microbial species live in the human ecosystem and comprise trillions of cells,<br />
making up 1%-3% of the total body mass. Conversely, microorganisms that are<br />
omnipresent in humans can sometimes turn virulent and cause sickness or even death.<br />
Researchers are focusing on improving the efficiency of medical treatments by<br />
developing a therapeutics course comprising of a subset of microorganisms.<br />
These research studies are currently under clinical development and are expected to fuel<br />
the market growth in the near future. Advancement in microbiome technologies would<br />
assist in determining the probable solutions for serious diseases; these technologies<br />
would thus improve healthcare outcomes. MicroBiome <strong>Therapeutics</strong> LLC, Enterome<br />
Bioscience, Pfizer and Johnson & Johnson are some of the key players in this market.<br />
Enterome has developed a diagnostic tool for the detection of inflammatory bowel<br />
disease by using a genetic sequencing platform.
Change language